‘’This whole concept of delaying is not something we will be doing.’’ ‘’We are not going to delay things unnecessarily here,’’ Marks said. The vaccines’ applications, he said, would be considered as soon as they are ready.
Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in an interview that the agency would not delay either vaccine to wait for the other.
